Bharat Biotech and Bilthoven Biologicals are on a mission to eradicate polio worldwide
Bharat Biotech joins with Bilthoven Biologicals; this alliance helps formulate safe vaccines for the worldwide distribution.
Breaking News
Apr 02, 2024
Mrudula Kulkarni
As per the reports, Bharat
Biotech International Limited (BBIL) has joined forces with Bilthoven
Biologicals (BBio) to eradicate polio worldwide. This collaboration aims
to enhance the production and security of supply for Oral Polio Vaccines
(OPV).
It is a milestone achieved by both BBIL and BBio. BBIL is a
leading global player in vaccine and biotherapeutic innovation. BBio is a
subsidiary of Serum Institute of India Private Limited, and together, they
shall bolster Oral Polio Vaccine (OPV) production and supply chain security.
Under this strategic alliance
announced on Tuesday, BBIL will procure essential drug substances from BBio for
OPV manufacturing. A formal agreement has been inked by representatives from
both organisations, solidifying BBIL's commitment to procure OPV drug
substances from BBio for distribution across India and globally.
Adar Poonawalla, CEO of Serum
Institute of India, expressed optimism about the potential impact
of this alliance on the global polio eradication efforts, emphasising its
significance in reducing the disease's burden.
Furthermore, both organisations
have promised to navigate regulatory approvals and licensing requirements to
facilitate the commercial launch of these vaccines. This strategic manoeuvre
highlights a concerted effort to combat polio more effectively. Together, they
promise to provide vulnerable populations with enhanced protection against this
debilitating disease.
Dr. Krishna Ella, Executive
Chairman of Bharat Biotech, pointed out the pivotal role of OPV in India's
Universal Immunization Programme (UIP) and BBIL's longstanding commitment to
global immunisation initiatives. He said that collaborating with BBio ensures a
reliable supply of OPV, thus supporting their mission to eradicate polio
worldwide.